Mount Nebo Capital Invests in Spermosens AB: Powering a Breakthrough in Fertility Diagnostics
Mount Nebo Capital is excited to announce our strategic investment in Spermosens AB (publ), a Swedish medtech company redefining male fertility diagnostics. Earlier this year, Spermosens secured SEK 10.8 million through a directed share issue led by Mount Nebo, alongside UNITY Innovation Alliance and a group of Nordic and German institutional investors and family offices. The financing is designed to support the company through commercialization milestones, with a target of reaching cash-flow positivity in H2 2026.
What Spermosens Does
Spermosens develops JUNO-Checked, a next-generation diagnostic platform that measures how well sperm bind to JUNO, the receptor on the human egg that is crucial for fertilization. The system generates a JUNO Score—a functional biomarker that provides information conventional semen analysis simply cannot capture. This mechanism-based readout has now been validated in peer-reviewed research and in clinical work, showing a statistically significant correlation with fertilization rates in IVF.
Why We Believe Spermosens Is Special
1) Clinically validated differentiation. Traditional semen tests focus on count and motility; JUNO-Checked captures the actual biology of fertilization. Recent clinical data from the Reproductive Medicine Center in Malmö demonstrate a robust link between the JUNO Score and IVF outcomes, including cases where men with “normal” semen parameters still show low JUNO binding—precisely the blind spot clinics struggle with today. Cision Nachrichten
2) Strong path to impact and revenues. Spermosens is pursuing a licensing-driven commercialization strategy with IVF clinics and sperm banks, supported by partners with regulatory and go-to-market expertise. The latest interim report lays out how JUNO-Checked could become a game-changing tool for the infertility market. Cision Nachrichten+1
3) Large, under-served market. With an IVF market around $25B (2023), mid-single-digit growth, and per-cycle success rates below 20%, the opportunity for better diagnostics is enormous. Even modest uplifts in outcomes translate into meaningful clinical value—and a compelling commercial model. Inderes+1
4) Credible scientific foundation. A 2025 peer-reviewed publication details the biosensor’s mechanism and the JUNO Score metric, reinforcing that this is not incremental tooling but new signal rooted in fertilization biology.
Strategic Support Around the Table
The investment consortium includes UNITY Innovation Alliance, which is engaged as a strategic and operational advisor on product development, certification, and market entry—accelerating the path from clinical validation to adoption.
As our Founding Partner Tom Walsh put it, “JUNO-Checked has the potential to revolutionize how male infertility is assessed.” That belief anchors our partnership with Spermosens as the company scales towards licensing and broader clinical use.
Looking Ahead
With fresh capital, clinical momentum, and a clear commercialization plan, Spermosens is positioned to help clinics personalize IVF decisions, improve success rates, and ultimately bring more families closer to parenthood. We’re proud to support this mission and excited for the milestones to come.
